Data for: Leptin and HPA axis activity in diabetic rats: Effects of adrenergic agonists

Published: 23 Nov 2018 | Version 1 | DOI: 10.17632/s7j49ntm6n.1

Description of this data

This study explores the effect of diabetes on norepinephrine release in the paraventricular nucleus of the hypothalamus and its relationship to circulating corticosterone. Leptin treatment helps to partially reverse the increase in noradrenergic activity in diabetic rats. Adrenergic agonists were used to reverse the effect of leptin. It was found that while the alpha adrenergic agonist clonidine reversed the effect of leptin on norepinephrine release towards the end of the observation period, the beta adrenergic agonist, isoproterenol, did not have a similar effect. We conclude that the hypothalamus remains sensitive to alpha adernergic agonists in diabetes, but not to beta adrenergic agonists. Leptin treatment produces a dramatic drop in circulating corticosterone indicating that the adrenals remain sensitive to leptin during diabetes. Moreover, both adrenergic agonists were able to counter leptin's effects on corticosterone. These results indicate that the adrenals continue to be sensitive to both adrenergic receptors in diabetes.

Experiment data files

This data is associated with the following publication:

Leptin and HPA axis activity in diabetic rats: Effects of adrenergic agonists

Published in: Brain Research

Latest version

  • Version 1


    Published: 2018-11-23

    DOI: 10.17632/s7j49ntm6n.1

    Cite this dataset

    MohanKumar, Sheba (2018), “Data for: Leptin and HPA axis activity in diabetic rats: Effects of adrenergic agonists”, Mendeley Data, v1


Views: 485
Downloads: 7


Leptin, Adrenergic Agonist, Hypothalamic Pituitary Adrenal Axis, Neuroendocrine Regulation


CC BY 4.0 Learn more

The files associated with this dataset are licensed under a Creative Commons Attribution 4.0 International licence.

What does this mean?

You can share, copy and modify this dataset so long as you give appropriate credit, provide a link to the CC BY license, and indicate if changes were made, but you may not do so in a way that suggests the rights holder has endorsed you or your use of the dataset. Note that further permission may be required for any content within the dataset that is identified as belonging to a third party.